Question explored with the scientific record
Started from a private conversation ↓
What is the 10-year recurrence risk for HER2+ by stage?
The short version: the 10-year recurrence risk for HER2-positive breast cancer by stage is not reported in the evidence provided, and the studies that exist do not stratify by stage at diagnosis for that endpoint.
The evidence you gave me does not contain a single study that reports 10-year recurrence risk for HER2-positive breast cancer broken down by stage at diagnosis. The closest is a 2025 I-SPY2 analysis of 395 HER2-positive patients that reports a 51% pathologic complete response rate and 4.4 years median follow-up, but it does not give 10-year recurrence by stage [11]. A 2016 meta-analysis of 5,768 HER2-positive patients found that achieving pCR was linked to better event-free survival (HR 0.37) and overall survival (HR 0.34), but again no stage-stratified 10-year recurrence numbers [15].
The 2006 IBCSG analysis of 9,524 women with early breast cancer reported that HER2-positive patients had a 2.7% risk of CNS metastasis as a first event at 10 years, and a 5.2% risk of CNS recurrence at any time by 10 years [2]. That is a specific organ site, not overall recurrence by stage.
| What is reported | Value | Source |
|---|---|---|
| HER2+ pCR rate (I-SPY2) | 51% | [11] |
| HER2+ pCR → EFS benefit (meta-analysis) | HR 0.37 | [15] |
| HER2+ CNS first event at 10 years | 2.7% | [2] |
| HER2+ CNS recurrence any time at 10 years | 5.2% | [2] |
The absence of stage-stratified 10-year recurrence data in the evidence is not proof that it does not exist in the literature. It means the retrieval did not surface it. The question is reasonable and clinically important, but the evidence here cannot answer it.
My call: the evidence provided does not contain 10-year recurrence risk for HER2-positive breast cancer by stage. The retrieval missed the question. Confidence: not clear.
Sources used 3
-
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
In a large retrospective analysis of 9,524 women with early breast cancer from IBCSG trials, the researchers identified clinical factors predicting CNS metastases but concluded that no high-risk subgroup existed to justify routine screening for occult CNS disease.
DOI: 10.1093/annonc/mdl064 -
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial
This study analyzes the prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in patients with triple-negative and HER2-positive breast cancer, revealing that tumor size at diagnosis is a key independent prognostic factor for t…
DOI: 10.1186/s13058-025-02070-1 -
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes
This meta-analysis evaluates the association between pathologic complete response (pCR) to neoadjuvant therapy in HER2-positive breast cancer and long-term outcomes, demonstrating that pCR is significantly linked to improved event-free survival and overall survival.
DOI: 10.1001/jamaoncol.2015.6113